|
- New Biomarkers Catch Tau Before It Tangles | ALZFORUM
Detecting toxic forms of tau before they weave into dense thickets of tangles could pave the way for earlier diagnosis and treatment of tauopathies, including Alzheimer’s disease In the February 10 Nature Medicine, researchers led by Thomas Karikari, University of Pittsburgh, unveil their
- Tau (AT8); Phospho Tau (Ser 202, Thr 205) - ALZFORUM
Hyperphosphorylated tau polymerizes into paired helical filaments, which aggregate to form neurofibrillary tangles, one of the defining lesions of Alzheimer’s disease Recognizes paired helical filament (PHF) tau Phosphorylation at serine 202 and threonine 205 is required for recognition by AT8
- Triple Trouble: New Knock-in Turbocharges Tauopathy
They accumulated hyperphosphorylated tau in their brains and lost synapses by approximately 15 months of age, but they had no tau oligomers capable of seeding aggregates Such “seeds” are a hallmark of human tauopathies Recognizing the need for models with more robust pathology at a younger age, the authors engineered the new triple-knock-ins
- LY3954068 | ALZFORUM
LY3954068 is a small interfering RNA (siRNA) that targets expression of the microtubule-associated binding protein tau No information is available about the makeup of LY3954068
- ApoE3 Christchurch Clings Tightly to Tau, Averting Tangles
To find out, the scientists turned to surface plasmon resonance, a technique that quantifies molecular interactions in real time It showed that ApoE3Ch clings onto tau monomers immobilized on sensor chips approximately eight times more tightly than does wild-type ApoE3 Similarly, in neuroblastoma cells, glutathione S-transferase-labelled tau and GFP-tagged ApoE3Ch bound tightly (image at right)
- Tau (CP-13) - ALZFORUM
This monoclonal antibody, generated against paired helical filaments (PHFs) isolated from Alzheimer’s brains, recognizes tau phosphorylated at serine 202 Recognizes tau phosphorylated at serine 202 Immunoreactivity present in Alzheimer’s disease and other tauopathies Immunoreactivity absent in
- MK-2214 | ALZFORUM
Background MK-2214 is an anti-tau monoclonal antibody This is likely an antibody to phosphorylated tau created at Teijin Pharma in Japan, and licensed by Merck in 2017 (press release)
- Tau (MC-1) - ALZFORUM
The interaction of MC-1 with recombinant tau suggests that post-translational modifications are not required to generate the MC-1 epitope However, it remains possible that post-translational modifications influence the ability of tau to adopt or maintain the conformation seen by MC-1
|
|
|